Brian Silver, J.D.

Brian Silver, J.D.

Former Chief Financial Officer and TreasureratTScan Therapeutics· In proxies 2022–2023

Pay in FY2023-1% from the year before · TScan Therapeutics stock +276.1% the same year

Brian Silver, J.D. was paid $1.6M in FY2023 (Dec), down 1%. TScan Therapeutics stock rose 276.1% that year.

Pay$100 in the stock at the end of FY21 → $130
Pay is from the Summary Compensation Table of each TScan Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. TScan TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer and Treasurer2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?